en · de · es
sr9009-notes.peptides1004.com › Info › Background And Receptor Mechanism — Deep Dive

Background And Receptor Mechanism — Deep Dive

By Editorial Desk · published 2025-08-23 · last reviewed 2025-10-06 · Info

NR1D2 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Related pages on this site

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Notes from published material

For example, for acidic foods, arrowroot is a better choice than cornstarch, which loses thickening potency in acidic mixtures. At pH levels below 4.5, guar gum has sharply reduced aqueous solubility, thus also reducing its thickening capability. If the food is to be frozen, tapioca or arrowroot are preferable over cornstarch, which becomes spongy when frozen.

Venlafaxine was originally marketed as Effexor in most of the world; generic venlafaxine has been available since around 2008 and extended-release venlafaxine has been available since around 2010. Venlafaxine is sold under many brand names worldwide. In some countries, Effexor is marketed by Viatris after Upjohn was spun off from Pfizer.

=== Shooting of student at law school === Duterte stated at a rally in April 2016 that he shot a fellow student who had bullied him about his Visayan origin as well as other students of the same ethnicity, while at San Beda law college. He said, "But the truth is, I'm used to shooting people. When we were about to graduate from San Beda, I shot a person." Duterte said that he shot the student in a corridor at the college when the said student called him names again. He later told a reporter that the student survived, but refused to answer any further questions about the incident. However, in an interview aired on 24 Oras and published on the official GMA News Online website on April 22, 2016, retired labor arbiter Arthur Amansec said Duterte and Octavio Goco at that time were both playing with a gun as it was normal for students to bring guns to school in the seventies. Amansec is Duterte's former classmate in San Beda College who witnessed the incident. He added that "the bullet hit the school's wooden floor and was embedded there." Amansec emphasized that Duterte and Goco remained friends until Goco died in the United States years later.

Sources: en.wikipedia.org

Further detail

In terms of the diagnosis of Becker muscular dystrophy symptom development resembles that of Duchenne muscular dystrophy. A physical exam indicates a lack of pectoral and upper arm muscles, especially when the disease is unnoticed through the early teen years. Muscle wasting begins in the legs and pelvis, and then progresses to the muscles of the shoulders and neck. Calf muscle enlargement (pseudohypertrophy) is quite obvious. Among the exams/tests performed are:

== History == DOPR was first described in the literature by Alexander Shulgin in 1970. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).

=== India === In India, one must obtain a bachelor's degree, which requires 4.5 years of training, along with a 1-year internship, followed by the NEET PG examination, which is one of the hardest examinations in India. Previous rank data shows that only top rankers take radiology, which means if the score is lower, one might get accepted into other branches, but not radiology. The radiology program is a post graduate 3-year program (MD/DNB Radiology) or a 2-year diploma (DMRD).

=== December === 2 December – Sir Chris Wormald is appointed as the new Cabinet Secretary and Head of the Civil Service, succeeding Simon Case, and will take up the role later in December. The Ministry of Defence begins a week-long series of war games to "stress test" how the United Kingdom's military resources would cope in the event of war. It is the first such exercise to involve representatives of the defence industry, alongside military commanders and officials. Addressing the Lord Mayor's Banquet, Prime Minister Keir Starmer rejects any suggestion that the UK must choose between closer ties with the EU and the US when Donald Trump becomes president. 3 December – The Financial Times reports that South Western Railway would become the first rail operator to be renationalised when its franchise expires after Parliament passed the Passenger Railway Services (Public Ownership) Act 2024 the previous week. Andrew RT Davies resigns as leader of the Welsh Conservatives shortly after narrowly surviving a vote of confidence by Senedd members by nine votes to seven. Kevin Craig, who was suspended as Labour's election candidate for Central Suffolk and North Ipswich after placing a bet that he would lose, is cleared of wrongdoing by the Gambling Commission. A proportional representation bill to replace first-past-the-post introduced by Liberal Democrat Sarah Olney passes on a symbolic vote. Scottish Labour leader Anas Sarwar blames an "administrative mess" after one of his party's newly elected councillors was disqualified from the job.

Sources: en.wikipedia.org

Background from the literature

==== Recombinant DNA ==== Biotechnology in the modern sense of genetic engineering began in the 1970s, with the invention of recombinant DNA techniques. Restriction enzymes were discovered and characterized in the late 1960s, following on the heels of the isolation, then duplication, then synthesis of viral genes. Beginning with the lab of Paul Berg in 1972 (aided by EcoRI from Herbert Boyer's lab, building on work with ligase by Arthur Kornberg's lab), molecular biologists put these pieces together to produce the first transgenic organisms. Soon after, others began using plasmid vectors and adding genes for antibiotic resistance, greatly increasing the reach of the recombinant techniques. Wary of the potential dangers (particularly the possibility of a prolific bacteria with a viral cancer-causing gene), the scientific community as well as a wide range of scientific outsiders reacted to these developments with both enthusiasm and fearful restraint. Prominent molecular biologists led by Berg suggested a temporary moratorium on recombinant DNA research until the dangers could be assessed and policies could be created. This moratorium was largely respected, until the participants in the 1975 Asilomar Conference on Recombinant DNA created policy recommendations and concluded that the technology could be used safely. Following Asilomar, new genetic engineering techniques and applications developed rapidly. DNA sequencing methods improved greatly (pioneered by Frederick Sanger and Walter Gilbert), as did oligonucleotide synthesis and transfection techniques.

The Assad regime had intensified its web censorship and cyber-monitoring during the course of the Syrian civil war and its cyber forces engaged in several social engineering techniques and surveillance measures such as phishing, malware attacks and the interception of Skype calls.

This means that the cancer cells don't look like normal epithelial cells and instead look more abnormal under a microscope with poorly differentiated tumors being very dangerous. These types of tumors grow faster, are more invasive, metastasize more, and have a worse prognosis. The galectin-7 protein still can't prevent the cancer entirely but there is still an association between its reduced presence and links to a worsened tumor prognosis. In a study transfecting and comparing the human colon carcinoma cell with a galectin-7 expression, it was found that the protein cells are more sensitive to apoptotic stimuli and has a reduced proliferation in vitro. The strong suppression of tumor formation was discovered when injected subcutaneously into immunodeficient mice. Galectin-7 was found to have a tumor-suppressive effect in the colon carcinoma model, though this is just one context dependent example of galectin-7 being used for anti-tumorigenic purposes.

The playground features train-themed equipment with an educational plaque explaining Jones' mobile refrigeration technology. In 2022, several Black-owned breweries honored Jones during Black History Month. They released commemorative beers featuring the likeness of notable figures in Black history, including Jones.

The Straw Hats' Jolly Roger was first used by protesters in Indonesia as early as October 2023 in Yogyakarta, during protests against the Gaza genocide. Student protesters in Indonesia begun flying the flag again in February 2025. Truck drivers began flying the Straw Hat Pirates' flag in late July 2025 to protest the prohibition of ODOL (over dimension, overload) trucks throughout several cities in Java, ongoing since 19 June 2025. The flag came into prominence during the 2025 Indonesian anti-government protests which started in the weeks leading up to Independence Day on 17 August. In July, President Prabowo Subianto had called on Indonesians to fly the red and white national flag to celebrate the 80th anniversary of the country's independence. Following the president's speech an apparel store received "thousands of orders" for the Jolly Roger flag, because "The anime reflects the injustice and inequality that Indonesians experience".

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Network